EL7.AI
StocksMedium•17 November 2026•
3 min read

ASP Isotopes Posts $30.371 Million Shareholder Loss in Third Quarter

Key Facts

1Shareholder loss was $30.371 million in the third quarter, compared with $12.617 million a year earlier.
2Quarterly revenue rose to $5.124 million from $1.271 million.
3Cash and cash equivalents totaled $201.7 million, which the company estimates is sufficient to cover expenses for at least 12 months.
4The company is targeting initial shipments of silicon-28 in the fourth quarter of 2026, and shipments of carbon-14 and ytterbium-176 in 2027.

ASP Isotopes reported a net loss attributable to shareholders of $30.371 million in the third quarter ended September 30, 2026, compared with $12.617 million in the same period of 2025, according to its quarterly financial report. Revenue rose to $5.124 million from $1.271 million, an increase of $3.853 million. But sales growth did not prevent the loss from widening, as operating expenses climbed to $41.308 million from $15.229 million. The company said higher revenue was linked to acquisitions and growth in existing sales, while spending to operate and develop the business remained high. The results show a divergence between revenue expansion and continued pressure on profitability during the quarter.

The company attributed part of its revenue to contributions of $0.8 million related to the NuMed acquisition and $0.9 million related to the ECNP acquisition. Sales in PET Labs' nuclear medicine pathway also increased by $1.3 million, and the company recorded $0.9 million in LNG sales following the Renergen acquisition. Gross profit was $793,000, compared with $242,000 a year earlier. The specialty isotopes segment posted gross profit of $1.626 million, while the helium and LNG segment recorded a gross loss of $833,000. This divergence reflects the varying contributions of the business activities to total gross profit during the period.

General and administrative expenses rose to $34.072 million in the quarter, compared with $12.131 million in the corresponding period of 2025. Research and development expenses increased to $7.236 million from $3.098 million. The company attributed part of the increase in research and development to a $2.330 million rise in contract services, consulting and professional services, as it worked to improve commercial production. For the first nine months of 2026, revenue totaled $14.427 million, compared with $3.571 million a year earlier. The segment operating loss for the same period widened to $99.598 million from $34.908 million.

The company said the helium and LNG segment's gross margin was negative 96% in the third quarter. It attributed this mainly to facility operating costs, while production remained below the level needed to absorb fixed costs. Management said it expects the segment's margins to improve in 2027 as production increases. Meanwhile, cash and cash equivalents totaled $201.7 million on September 30, 2026. The company estimates its current resources are sufficient to cover operating expenses and capital expenditures for at least 12 months from the date the financial statements were issued.

The company is targeting initial shipments of enriched silicon-28 in the fourth quarter of 2026, while shipments of enriched carbon-14 could begin in 2027, and it is targeting the start of ytterbium-176 shipments in the same year. These dates mark upcoming stages in its commercial isotope plans, alongside its current activity in nuclear medicine, helium and LNG. The company warned that it may need additional funding through equity or debt issuance or other sources of capital. It added that it may be unable to raise funds or enter into financing arrangements when needed on favorable terms, or may be unable to do so at all. The warning puts liquidity and the timing of shipment plans among the factors markets will monitor in coming periods.

Open on chart